medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2011, Number 4

<< Back Next >>

Rev Mex Urol 2011; 71 (4)

MicroRNA determination in urine for prostate cancer detection in Mexican patients at the Hospital General 'Dr. Manuel Gea González'

Ahumada-Tamayo S, Saavedra-Briones D, Cantellano-Orozco M, Salido-Guadarrama A, Rodríguez-Dorantes M, Urdiales-Ortiz A, Hernández-Castellanos V, Merayo-Chalico C, Sánchez-Turati G, Santana-Ríos Z, Fulda-Graue S, Pérez-Becerra R, Martínez JA, Fernández-Noyola G, Muñoz-Ibarra E, Camacho-Castro A, García-Salcido F, Morales-Montor G, Pacheco-Gahbler C

Language: Spanish
References: 34
Page: 213-217
PDF size: 377.70 Kb.


ABSTRACT

Multiple molecular markers have been studied in the search for a diagnostic test that will increase the probability of prostate cancer detection and reduce the number of unnecessary biopsies. MicroRNAs are constitutive elements of molecular identification of benign prostatic hyperplasia and prostate cancer and represent a possible tool that could contribute to the development of new opportune and reliable diagnostic strategies for prostate disease.
Objective: To determine the association of microRNA in urine for prostate cancer diagnosis in Mexican patients at Hospital General “Dr. Manuel Gea González”.
Methods: Thirty patients that underwent prostate biopsy from May-July 2010 were included in the study. A urine sample was taken from each one after prostate massage prior to biopsy, determining microRNA concentration from the sample. Samples with concentrations above 50 ng/mL of microRNA (18/30 samples) were selected; from these samples microRNA amplification and microRNA-373 quantification with real time polymerase chain reaction method were carried out.
Results: Of the eighteen patients with microRNA above 50 ng/mL, nine had positive biopsy and nine had negative biopsy. Of the microRNAs-373 quantified, fifty microRNAs showed expression in the eighteen replicas (100%) that were carried out; only twenty-one of the fifty micro RNAs were repeated in all samples; nineteen of them were overexpressed (miR-196b, -574-3p, let-7b, -7c, -7d, 7e,-7g, miR -200b, -149, -20b, -17, -184, -20a, -106a, -671-3p,-148a, -429, -31, -100) and only two were underexpressed (miR -150, -328).
Conclusions: A group of 21 microRNAs was determined that showed statistically significant expression in the prostate cancer sample group.


REFERENCES

  1. García M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.

  2. INEGI. Estadísticas a propósito del día mundial contra el cáncer; 2009.

  3. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursors and pathobiology. Urology 2003;62(5Suppl1):55-62.

  4. Schulz WA, Burchardt M, Cronauer MV. Molecular biology of prostate cancer. Mol Hum Reprod 2003;9:437-48.

  5. Rubin MA, De Marzo AM. Molecular genetics of human prostate cancer. Mod Pathol 2004;17:380-8.

  6. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-71.

  7. Reynolds MA, Kastury K, Groskopf J. Molecular markers for prostate cancer. Cancer Lett 2007;249:5-13.

  8. You J, Cozzi P, Walsh B. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit Rev Oncol Hematol 2010;73:10-22.

  9. Bussemakers MJ, van Bokhoven A, Verhaegh GW. DD3: a new prostate- specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.

  10. Rubin MA, Zhou M, Dhanasekaran SM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-1670.

  11. Tomlins SA, Laxman B, Varambally S. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-88.

  12. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Bio 2007;23:175-205.

  13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.

  14. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-8.

  15. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004;10:1957-66.

  16. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6:376-85.

  17. Lund E, Güttinger S, Calado A Nuclear export of microRNA precursors. Science 2004;303:95-8.

  18. Ro S, Park C, Young D. Tissue-dependent paired expression of miRNAs. Nucleic Acids Res 2007;35:5944-53.

  19. Brennecke J, Stark A, Russell RB. Principles of microRNA-target recognition. PLoS. Biol. 2005 3, e85. PLoS Biol 2005;3:e85.

  20. Rajewsky N, Socci ND. Computational identification of microRNA targets. Dev Biol 2004;267:529-35.

  21. Liu J, Carmell MA, Rivas FV. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004;305:1437-41.

  22. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9:102-14.

  23. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005;7:719-23.

  24. Parker R, Sheth U. P bodies and the control of mRNA translation and degradation. Mol Cell 2007;25:635-46.

  25. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-4.

  26. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75:855-62.

  27. Lu J, Getz G, Miska EA, Alvarez-Saavedra E. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.

  28. Asangani IA, Rasheed SA, Nikolova DA. MicroRNA-21 (miR-21) posttranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27:2128-36.

  29. Zhu S, Wu H, Wu F, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Re 2008;18:350-9.

  30. Hayashita Y, Osada H, Tatematsu Y. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.

  31. Tong AW, Fulgham P, Jay C. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009;16:206-16.

  32. Chim SS, Shing TK, Hung EC. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008;54:482-90.

  33. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.

  34. Pang Y, Young CY, Yuan H, et al. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 2010;42:363-9.




2020     |     www.medigraphic.com